Literature DB >> 20520288

Cocaine choice in humans during D-amphetamine maintenance.

Craig R Rush1, William W Stoops, Rajkamur J Sevak, Lon R Hays.   

Abstract

The results of preclinical laboratory experiments and clinical trials indicate that agonist replacements such as d-amphetamine may be a viable option for managing cocaine dependence. This study determined the effects of d-amphetamine maintenance on cocaine choice behavior in human participants. We predicted that d-amphetamine maintenance would reduce cocaine choice. Nine cocaine-dependent participants completed the study. Two d-amphetamine maintenance conditions were completed in a counterbalanced order (0 and 40 mg/d). After 3 to 5 days of placebo or d-amphetamine maintenance, the participants completed 5 experimental sessions. During these sessions, the participants first sampled the placebo (ie, 4 mg of intranasal cocaine) identified as drug A. The participants then sampled a second intranasal drug dose (4, 10, 20, or 30 mg of cocaine) identified as drug B. The participants then made 6 discrete choices between drugs A and B. Drug choices were separated by 45 minutes. The primary outcome measure was the number of cocaine choices. All doses of cocaine were chosen significantly more than placebo during both maintenance conditions (ie, placebo and d-amphetamine). Choice of the 20-mg dose of cocaine was significantly lower during d-amphetamine maintenance relative to when this cocaine dose was tested during placebo-d-amphetamine maintenance. Cocaine produced prototypical subject-rated drug effects (eg, good effects, like drug, willing to take again). These effects were not altered to a significant degree by d-amphetamine maintenance. Cocaine was well tolerated during D-amphetamine maintenance, and no unexpected or serious adverse events occurred. These results are concordant with those of previous preclinical experiments, human laboratory studies, and clinical trials that suggest that agonist replacement therapy may be a viable strategy for managing cocaine dependence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520288     DOI: 10.1097/JCP.0b013e3181d21967

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  52 in total

1.  Influence of acute bupropion pre-treatment on the effects of intranasal cocaine.

Authors:  William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Addiction       Date:  2012-02-11       Impact factor: 6.526

Review 2.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

Review 3.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 4.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 5.  Psychostimulant treatment of cocaine dependence.

Authors:  John J Mariani; Frances R Levin
Journal:  Psychiatr Clin North Am       Date:  2012-04-26

6.  Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.

Authors:  Craig R Rush; William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

7.  The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.

Authors:  Anushree N Karkhanis; Thomas J R Beveridge; Bruce E Blough; Sara R Jones; Mark J Ferris
Journal:  Drug Alcohol Depend       Date:  2016-06-25       Impact factor: 4.492

8.  Methamphetamine self-administration in humans during D-amphetamine maintenance.

Authors:  Erika Pike; William W Stoops; Lon R Hays; Paul E A Glaser; Craig R Rush
Journal:  J Clin Psychopharmacol       Date:  2014-12       Impact factor: 3.153

9.  N-Acetylcysteine reduces cocaine-cue attentional bias and differentially alters cocaine self-administration based on dosing order.

Authors:  B Levi Bolin; Joseph L Alcorn; Joshua A Lile; Craig R Rush; Abner O Rayapati; Lon R Hays; William W Stoops
Journal:  Drug Alcohol Depend       Date:  2017-06-29       Impact factor: 4.492

10.  Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

Authors:  Suzette M Evans; Richard W Foltin; Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Kim D Janda; Stephen M Kaminsky; Ronald G Crystal
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.